|
|
||||||||
Department of Cardiothoracic Sciences, Second University of Naples, Department of Cardiovascular Surgery and Transplants, V. Monaldi Hospital, Via Cassano 150, Naples, 80144 Italy
(Email: marianovicchio{at}libero.it).
We read with interest the letter by Gasparovic [1] regarding the issue of prosthesis patient mismatch (PPM) in elderly patients. We have long studied mechanical prosthesis implants in the elderly [2–4].
We are not reluctant to use biological valves as Gasparovic [1] states, but we have developed our institutional policy for more frequent use of mechanical valves because of our successful management of anticoagulation in elderly people [5].
Gasparovic [1] alleges that we have "emphasized the greater durability of mechanical prosthesis in comparison to tissue valves" but our study was not a comparative analysis. Our study focused on satisfactory hemodynamic performance of small-sized mechanical valves in the elderly, on the irrelevance of PPM to long-term mortality, the incidence of valve-related complications, and the quality of life.
We reported that in our study population the PPM did not reduce survival and quality of life. Considering the increased life expectancy in the world and the safety of anticoagulation in the elderly, mechanical valve implantation could reduce the risk of reoperation in elderly patients with bioprosthetic structural degeneration. When asked to choose a valve substitute, our elderly patients are generally more threatened by a possible reoperation than by possible anticoagulation-related complications that can be avoided by close follow-up.
Most authors alleged that oral anticoagulation in the elderly has a high risk of hemorrhagic events.
Others maintain that monitoring anticoagulation reduces the quality of life. In our studies, we have shown that freedom from hemorrhagic complications is 98.3% ± 0.007 at 10 and 15 years [5, 6]. Moreover, quality-of-life scores are more than satisfying.
Gasparovic [1] mentioned transcatheter valve-in-valve prosthesis procedures and cited an article on 40 patients with a mean follow-up of 144 days and hospital mortality of 17.5%. Although those promising procedures need further assessment in the long term and in larger cohorts, our patient population antedated those innovations.
We believe that the reliability of new, less invasive procedures for the elderly or high-risk patients should always be compared with traditional series like ours.
| References |
|---|
|
|
|---|
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |